You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

32 search results for: disease control

expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

10 min

Rhinology

Prof. Peter Hellings and Prof. Eugenio De Corso discuss viewpoints on the emerging definitions of disease remission in CRSwNP.

Importance of Achieving <b>Disease</b> <b>Control</b> in Adults With Moderate-to-Severe AD

expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min

Dermatology

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

IRS-ISIAN 2024 | Guideline Definitions of <b>Control</b> in CRSwNP

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

Infographic

Importance of Monitoring and Maintenance in EoE

5 min

Gastroenterology

Learn about patient concerns in EoE and the benefits of adequate monitoring and effective maintenance therapy on disease control and QoL.

What do we mean by <b>disease</b> <b>control</b> in AD?

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

Asthma Remission: Moving Beyond <b>Control</b>

interactivity

Asthma Remission: Moving Beyond Control

5 min

Pulmonology

Learn about the proposed framework for clinical remission in patients with asthma.

<b>Disease</b> Modification Concepts in AD

expert video

Disease Modification Concepts in AD

1 min

Type 2 Inflammation

Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.

expert video

GOLD 2023 | Clinical Presentation of COPD and Disease Burden

9 min

Pulmonology

Dr. Igor Barjaktarevic discusses the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of recognizing the heterogeneity of COPD.

interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

5 min

Pulmonology

Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.

interactivity

Type 2 Inflammation Digital Assessment Tool

4 min

Pulmonology

Learn how to assess patients for the presence of uncontrolled asthma driven by underlying type 2 inflammation.

expert video

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD

29 min

Pulmonology

Drs. Stephen Rennard and Igor Barjaktarevic discuss the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of recognizing the heterogeneity of COPD.

expert video

GOLD 2023 | Role of Underlying Inflammation in COPD Pathology and Clinical Features

10 min

Pulmonology

Dr Igor Barjaktarevic discusses the role of underlying inflammation in COPD pathology and associated clinical features and explore the importance of biomarker assessments and endotyping in COPD

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region